硝苯地平 - CAS:21829-25-4 - CAS号查询_生物试剂_化学试剂_分析试剂

中文名称:	硝苯地平促销
英文名称:	Nifedipine
别名:	硝苯地平 1,4-Dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid dimethyl ester
CAS No:	21829-25-4	分子式:	C₁₇H₁₈N₂O₆	分子量:	346.33
CAS No:	21829-25-4
分子式:	C₁₇H₁₈N₂O₆
分子量:	346.33
MDL:	MFCD00057326	EINEC:	244-598-3
EINEC:	244-598-3

安全技术说明书(PDF) MSDS(PDF) 点击下载技术规格说明书(PDF) 点击下载产品说明书(PDF)

N70013 硝苯地平 ≥98% (psaitong)

相关产品

三苯基溴化锍
CAS No：3353-89-7
三(4-甲苯基)锍六氟磷酸盐
CAS No：146062-15-9
2-异丙基硫杂蒽酮
CAS No：5495-84-1
稳定剂UV-3346
CAS No：82451-48-7
2-羟基-4’-(2-羟乙氧基)-2-甲基苯丙酮
CAS No：106797-53-9
硝苯地平
CAS No：21829-25-4

熔点：

173-177°C

外观与性状：

黄色粉末

包装规格：

5g 25g 100g in glass bottle

溶解性：

溶于DMSO(50mg/ml)、甲醇和乙醇

产品描述：

基本信息

产品编号：	N70013
产品名称：	Nifedipine
CAS:	21829-25-4	储存条件	粉末	室温避光	四年
分子式：	C17H18N2O6		溶于液体	-80℃(避光)	6个月
分子量：	346.33			-20℃(避光)	1个月
化学名：	1,4-Dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid dimethyl ester
Solubility (25°C)：
体外:	DMSO	69mg/mL (199.23mM)
	Ethanol	15mg/mL (43.31mM)
	Water	Insoluble
体内(现配现用):	1.请依序添加每种溶剂：10% DMSO→40% PEG300→5% Tween-80→45% saline Solubility:≥2.5mg/mL(7.22mM);Clear solution
	此方案可获得 ≥ 2.5 mg/mL (7.22 mM，饱和度未知) 的澄清溶液。以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
＜1mg/ml表示微溶或不溶。
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。

制备储备液

浓度溶液体积质量	1mg	5mg	10mg
1mM	2.8874mL	14.4371mL	28.8742mL
5mM	0.5775mL	2.8874mL	5.7748mL
10mM	0.2887mL	1.4437mL	2.8874mL

生物活性

产品描述	一种选择性钙通道蛋白抑制剂。
靶点	Calcium Channel;Autophagy
体外研究	Nifedipine (BAY-a-1040) (100μM) significantly lowers the viability of the WKPT-0293 Cl.2 Cells,and treatment of nifedipine (10 or 100μM) plus FAC induces a significant reduction in cell viability,but there are no significant differences in viability between the control cells and the cells treated with 100μM of FAC or 1 and 10μM of nifedipine.Nifedipine (BAY-a-1040) (1,10,or 100μM) significantly increases iron level in WKPT-0293 Cl.2 cells.Nifedipine treatment also increases expression of TfR1,DMT1+IRE and DMT1-IRE in WKPT-0293 Cl.2 cells.In addition,co-treatment with nifedipine (100μM) and FAC (100μM) increases TfR1,DMT1+IRE and DMT1-IRE expression in WKPT-0293 Cl.2 cells.Nifedipine plus ritodrine produces a significantly greater inhibition of contractility than each drug alone in the midrange of concentrations.The combination of nifedipine plus nitroglycerin or nifedipine plus atosiban produces a significantly greater inhibition than nitroglycerin or atosiban alone but not greater than nifedipine.The combination of nifedipine plus NS-1619 (Ca2+-activated K+[BKCa] channel opener) reduces the inhibitory effect of each drug.Nifedipine (BAY-a-1040) (2μM) significantly inhibits P.capsici mycelial growth and sporulation.Nifedipine (BAY-a-1040)-induced inhibition of mycelial growth is calcium-dependent.Nifedipine (0.5μM) increases P.capsici sensitivity to H2O2 in a calcium-dependent manner.Nifedipine inhibition of P.capsici virulence and expression of genes involved in pathogenicity.
体内研究	In Nifedipine (BAY-a-1040) (50mg/kg)- and CsA-treated rats,the BL dimensions (BLi and BLk),MD dimensions (MDk) and vertical dimensions (VHi and VHk) are significantly increased (P<0.05) at the end of the 4th week.

推荐实验方法(仅供参考)

细胞实验:

Cell viability is assessed using an MTT assay.Briefly,a total of 25μL MTT (1g/L in PBS) is added to each well before incubation is conducted at 37℃ for 4h.The assay is stopped by the addition of a 100μL lysis buffer (20% SDS in 50% N’Ndimethylformamide,pH 4.7).Optical density (OD) is measured at the 570nm wavelength by the use of an ELX-800 microplate assay reader and the results are expressed as a percentage of the absorbance measured in the control cells.

动物实验:
All the 30 rats are randomLy distributed into three equal groups of ten animals each.Group 1 (control) receive olive oil for the 8 weeks.Group 2 and Group 3 receive a combination of CsA (30mg/kg body weight) and Nf (50mg/kg body weight) in olive oil for 8 weeks.In Group 3 rats,Azi (10mg/kg body weight) is added to this regimen,in the 5th week.The total study period is 8 weeks.

保存条件：

室温避光

UN码：

HazardClass：

危害声明：

安全说明：

搜索质检报告(COA)

参考文献 & 客户发表文献

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为：
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

质量 =

浓度 *

体积 *

分子量

*选择对应的单位 *空出希望得到的变量，填写另外两个变量

用本工具协助配置特定浓度的溶液，使用的计算公式为：
开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为：C1V1 = C2V2 ( 输入输出 )

* = *

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

摩尔浓度计算公式

稀释公式

连续稀释计算器方程

连续稀释

计算结果